Application of next-generation sequencing in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma.
• Despite rituximab, 30% of DLBCL patients have a poor prognosis, highlighting the need for improved strategies.
• Molecular heterogeneity significantly impacts DLBCL diagnosis, treatment, and patient outcomes.

Purpose of the Study:

• To review the advancements in next-generation sequencing (NGS) for DLBCL.
• To explore the role of NGS in DLBCL classification and diagnosis.
• To discuss the application of NGS in predicting prognosis and guiding molecular targeted therapy for DLBCL.

Main Methods:

• Literature review of research on next-generation sequencing in DLBCL.
• Analysis of studies focusing on NGS applications in DLBCL classification and diagnosis.
• Examination of research on NGS for prognostic assessment and targeted therapy development in DLBCL.

Main Results:

• NGS has revealed significant molecular heterogeneity within DLBCL subtypes.
• NGS technologies are improving the accuracy of DLBCL diagnosis and classification.
• NGS data are increasingly used to predict patient prognosis and identify therapeutic targets.

Conclusions:

• Next-generation sequencing is a pivotal technology in understanding DLBCL complexity.
• NGS facilitates personalized treatment strategies, improving outcomes for DLBCL patients.
• Continued research using NGS will drive further progress in precision medicine for DLBCL.